,trastuzumab deruxtecan
Daiichi Sankyo,AstraZeneca
['breast']
destiny breast 04 trial now out in the nejm! in her2 low pts the median pfs was 9.9m in the tdxd group and 5.1 m in the physician s choice group and os was 23.4 mo and 16.8 m respectively #asco2022 
Breast cancer specialist. Shoe lover. Cupcake connoisseuse. Opinions are my own, RTs not an endorsement.